EGFR and neoplasm: In another study, engineered EVs modified with GE11 peptides selectively targeted EGFR-positive tumor cells and delivered Dox, showing higher targeting efficiency, increased apoptosis, and reduced cytotoxicity to normal cells compared to non-modified EVs and free Dox treatments [145].